Unknown

Dataset Information

0

A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge.

ABSTRACT: Virus-like particles (VLPs) present viral antigens in a native conformation and are effectively recognized by the immune system and therefore are considered as suitable and safe vaccine candidates against many viral diseases. Here we demonstrate that chimeric VLPs containing Rift Valley fever virus (RVFV) glycoproteins G(N) and G(C), nucleoprotein N and the gag protein of Moloney murine leukemia virus represent an effective vaccine candidate against Rift Valley fever, a deadly disease in humans and livestock. Long-lasting humoral and cellular immune responses are demonstrated in a mouse model by the analysis of neutralizing antibody titers and cytokine secretion profiles. Vaccine efficacy studies were performed in mouse and rat lethal challenge models resulting in high protection rates. Taken together, these results demonstrate that replication-incompetent chimeric RVF VLPs are an efficient RVFV vaccine candidate.

SUBMITTER: Mandell RB 

PROVIDER: S-EPMC2813982 | biostudies-literature | 2010 Feb

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge.

Mandell Robert B RB   Koukuntla Ramesh R   Mogler Laura J K LJ   Carzoli Andrea K AK   Freiberg Alexander N AN   Holbrook Michael R MR   Martin Brian K BK   Staplin William R WR   Vahanian Nicholas N NN   Link Charles J CJ   Flick Ramon R  

Virology 20091124 1

Virus-like particles (VLPs) present viral antigens in a native conformation and are effectively recognized by the immune system and therefore are considered as suitable and safe vaccine candidates against many viral diseases. Here we demonstrate that chimeric VLPs containing Rift Valley fever virus (RVFV) glycoproteins G(N) and G(C), nucleoprotein N and the gag protein of Moloney murine leukemia virus represent an effective vaccine candidate against Rift Valley fever, a deadly disease in humans  ...[more]

Similar Datasets

Unknown MVA Vectored Vaccines Encoding Rift Valley Fever Virus Glycoproteins Protect Mice against Lethal Challenge in the Absence of Neutralizing Antibody Responses.
| S-EPMC7157666 | biostudies-literature
Unknown A Recombinant Rift Valley Fever Virus Glycoprotein Subunit Vaccine Confers Full Protection against Rift Valley Fever Challenge in Sheep.
| S-EPMC4906348 | biostudies-other
Unknown Two monoclonal antibodies against glycoprotein Gn protect mice from Rift Valley Fever challenge by cooperative effects.
| S-EPMC7089562 | biostudies-literature
Unknown Lethal Mutagenesis of Rift Valley Fever Virus Induced by Favipiravir.
| S-EPMC6658772 | biostudies-literature
Unknown Curcumin inhibits Rift Valley fever virus replication in human cells.
| S-EPMC3460426 | biostudies-other
Unknown Single-dose immunization with virus replicon particles confers rapid robust protection against Rift Valley fever virus challenge.
| S-EPMC3318656 | biostudies-literature
Unknown Recombinant Rift Valley fever vaccines induce protective levels of antibody in baboons and resistance to lethal challenge in mice.
| S-EPMC3169153 | biostudies-other
Unknown Metal coordinating inhibitors of Rift Valley fever virus replication.
| S-EPMC9481026 | biostudies-literature
Unknown Potent neutralizing human monoclonal antibodies protect from Rift Valley fever encephalitis.
| S-EPMC11457859 | biostudies-literature
Unknown Livestock Challenge Models of Rift Valley Fever for Agricultural Vaccine Testing.
| S-EPMC7266933 | biostudies-literature